Fig. 3.
Modelled progression-free survival from KEYNOTE-024 for pembrolizumab and standard-of-care arms. BICR blinded independent central review, ITT intention-to-treat, PFS progression-free survival, SoC standard of care
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.